- Home
- IAS vs GPCR Comparison
IAS vs GPCR Comparison
Compare IAS & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAS
- GPCR
- Stock Information
- Founded
- IAS 2009
- GPCR 2016
- Country
- IAS United States
- GPCR United States
- Employees
- IAS N/A
- GPCR N/A
- Industry
- IAS Computer Software: Programming Data Processing
- GPCR
- Sector
- IAS Technology
- GPCR
- Exchange
- IAS Nasdaq
- GPCR Nasdaq
- Market Cap
- IAS 1.3B
- GPCR 1.1B
- IPO Year
- IAS 2021
- GPCR 2023
- Fundamental
- Price
- IAS $8.14
- GPCR $21.76
- Analyst Decision
- IAS Buy
- GPCR Strong Buy
- Analyst Count
- IAS 11
- GPCR 8
- Target Price
- IAS $13.55
- GPCR $79.29
- AVG Volume (30 Days)
- IAS 1.4M
- GPCR 755.1K
- Earning Date
- IAS 05-12-2025
- GPCR 05-08-2025
- Dividend Yield
- IAS N/A
- GPCR N/A
- EPS Growth
- IAS 2607.38
- GPCR N/A
- EPS
- IAS 0.29
- GPCR N/A
- Revenue
- IAS $549,637,000.00
- GPCR N/A
- Revenue This Year
- IAS $13.38
- GPCR N/A
- Revenue Next Year
- IAS $11.39
- GPCR N/A
- P/E Ratio
- IAS $28.38
- GPCR N/A
- Revenue Growth
- IAS 13.84
- GPCR N/A
- 52 Week Low
- IAS $6.26
- GPCR $13.22
- 52 Week High
- IAS $13.62
- GPCR $62.74
- Technical
- Relative Strength Index (RSI)
- IAS 60.22
- GPCR 39.75
- Support Level
- IAS $7.79
- GPCR $22.09
- Resistance Level
- IAS $8.11
- GPCR $24.98
- Average True Range (ATR)
- IAS 0.25
- GPCR 1.64
- MACD
- IAS 0.02
- GPCR -0.54
- Stochastic Oscillator
- IAS 38.80
- GPCR 4.64
About IAS Integral Ad Science Holding Corp.
Integral Ad Science Holding Corp is a digital advertising verification company. The cloud-based technology platform of the company delivers independent measurement and verification of digital advertising across all devices, channels, and formats, including desktop, mobile, connected TV, social, display, and video. Geographically, the company derives a majority of its revenue from the Americas region.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.